Nuclear β-catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of bone

[1]  R. Randall,et al.  Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone , 2020, Current Treatment Options in Oncology.

[2]  C. Zúñiga.  [Giant cell tumor]. , 2020, Revista medica hondurena.

[3]  C. Plass,et al.  Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells. , 2019, Cancer letters.

[4]  Yong-Koo Park,et al.  Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. , 2018, Human pathology.

[5]  Ping Huang,et al.  miR-125a Promotes the Progression of Giant Cell Tumors of Bone by Stimulating IL-17A and β-Catenin Expression , 2018, Molecular therapy. Nucleic acids.

[6]  H. Yoshikawa,et al.  Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study , 2018, World Journal of Surgical Oncology.

[7]  Y. Oda,et al.  Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line , 2018, Analytical cellular pathology.

[8]  Wei Zhang,et al.  Deacetylmycoepoxydiene is an agonist of Rac1, and simultaneously induces autophagy and apoptosis , 2018, Applied Microbiology and Biotechnology.

[9]  K. Ohashi,et al.  Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses , 2018, Histopathology.

[10]  M. Allison,et al.  Anthropometric measures of obesity and renal artery calcification: Results from the Multi-Ethnic Study of Atherosclerosis. , 2018, Atherosclerosis.

[11]  M. Masuda,et al.  Wnt/β-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland. , 2018, Pathology, research and practice.

[12]  T. Komori.  Runx2, an inducer of osteoblast and chondrocyte differentiation , 2018, Histochemistry and Cell Biology.

[13]  Y. Oda,et al.  Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. , 2017, Human pathology.

[14]  T. Barth,et al.  H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant , 2017, Histopathology.

[15]  M. Saegusa,et al.  Possible role of nuclear β‐catenin in resistance to preoperative chemoradiotherapy in locally advanced rectal cancer , 2017, Histopathology.

[16]  J. Sopta,et al.  Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67 , 2016, International Orthopaedics.

[17]  Ping Wen,et al.  WNT/β-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. , 2016, Experimental cell research.

[18]  T. Ueda,et al.  Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Ghert,et al.  A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab. , 2014, The Journal of bone and joint surgery. American volume.

[20]  Yongping Cai,et al.  β-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma. , 2014, Human pathology.

[21]  H. Okamoto,et al.  A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/β-catenin pathway. , 2014, Chemistry & biology.

[22]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[23]  J. Healey,et al.  Targeting the Giant Cell Tumor Stromal Cell: Functional Characterization and a Novel Therapeutic Strategy , 2013, PloS one.

[24]  I. D'alimonte,et al.  Wnt Signaling Behaves as a “Master Regulator” in the Osteogenic and Adipogenic Commitment of Human Amniotic Fluid Mesenchymal Stem Cells , 2013, Stem Cell Reviews and Reports.

[25]  Y. Oda,et al.  Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma , 2013, British Journal of Cancer.

[26]  T. He,et al.  Wnt signaling in bone formation and its therapeutic potential for bone diseases , 2013, Therapeutic advances in musculoskeletal disease.

[27]  B. Williams,et al.  Wnt signaling in bone development and disease: making stronger bone with Wnts. , 2012, Cold Spring Harbor perspectives in biology.

[28]  Yoshiya Tanaka,et al.  Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. , 2012, Arthritis and rheumatism.

[29]  David M. Thomas,et al.  Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone , 2012, Clinical Cancer Research.

[30]  Y. Iwamoto,et al.  The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas , 2012, Cancer.

[31]  K. Harimaya,et al.  Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone , 2010, Journal of orthopaedic surgery and research.

[32]  David M. Thomas,et al.  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. , 2010, The Lancet. Oncology.

[33]  M. Nakashima,et al.  Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. , 2009, Pathology, research and practice.

[34]  M. Alberghini,et al.  Histogenetic Characterization of Giant Cell Tumor of Bone , 2008, Clinical orthopaedics and related research.

[35]  David A. Williams,et al.  Rac1 Activation Controls Nuclear Localization of β-catenin during Canonical Wnt Signaling , 2008, Cell.

[36]  H. Tsuchiya,et al.  Osteoblast lineage properties in giant cell tumors of bone , 2005, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[37]  Janet L Stein,et al.  Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression* , 2005, Journal of Biological Chemistry.

[38]  David M. Thomas,et al.  Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. , 2005, The American journal of pathology.

[39]  S. Kumta,et al.  Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. , 2004, Bone.

[40]  A. Cox,et al.  Rac1 and Rac3 are targets for geranylgeranyltransferase I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling. , 2003, Cancer research.

[41]  S. Ushigome,et al.  Giant cell tumor of bone: An immunohistochemical comparative study , 1998, Pathology international.

[42]  V. Fornasier,et al.  The prognostic significance of histomorphometry and immunohistochemistry in giant cell tumors of bone. , 1996, Human pathology.

[43]  G. Stein,et al.  Transcriptional control of osteoblast growth and differentiation. , 1996, Physiological reviews.

[44]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[45]  Dylan M. Marchione,et al.  H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone , 2020 .

[46]  M. Agarwal,et al.  Giant Cell Tumor of Bone - An Overview. , 2016, The archives of bone and joint surgery.

[47]  Gurmit Singh,et al.  Giant cell tumor of bone: a basic science perspective. , 2013, Bone.

[48]  松林 昌平.  Immunohistochemical analyses of β-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB) : a possible role of Wnt pathway in GCTB tumorigenesis , 2009 .

[49]  H. Yoshida,et al.  Giant cell tumor of bone , 2004, Virchows Archiv A.

[50]  W F Bodmer,et al.  A basic science perspective. , 1995, Cancer surveys.